arrow
G

Gloria Iacoboni

cell engineering and hematologic immunotherapy lab
H指数:28
被引数:3,793

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy

巩固性同种异基因HCT与观察等待策略的比较:CAR T细胞治疗后早期丧失B细胞 aplasia的B细胞急性淋巴细胞白血病患者

2026-09-290
PRE
Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party

套细胞淋巴瘤患者中真实世界CAR-T实践模式:EBMT淋巴瘤工作组发起的一项国际调查

2026-08-180
PRE
Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma

氟达拉滨暴露对大B细胞淋巴瘤患者CAR T细胞疗效的影响

2026-06-120
OAAI
Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma

Prior Bendamustine Exposure对复发/难治性滤泡性淋巴瘤中双特异性抗体疗效的影响

2026-01-090
OAAI
Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy

迈向个性化淋巴细胞清除:接受CAR T细胞疗法的患者群体药代动力学氟达拉滨模型

2025-12-100
OA
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3

Brexucabtagene autoleucel 用于 BTKi 初治的复发/难治性套细胞淋巴瘤:ZUMA-2 研究队列 3 的主要分析

Blood
IF23.1
2025-10-310
PRE
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers

炎症为基础评分在复发/难治性LBCL患者接受CD3xCD20双特异性T细胞接合物治疗中的预后价值

2025-10-240
OAAI
#3310 Long-term outcomes of patients developing acute kidney injury after CAR-T cell therapy for relapsed/refractory hematological malignancies

#3310 接受CAR-T细胞治疗复发/难治性血液系统恶性肿瘤后发生急性肾损伤患者的长期结局

2025-10-210
OA
Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy

大B细胞淋巴瘤患者接受CAR T细胞治疗时的患者选择与治疗结果随时间的变化

2025-09-300
PRE
Use of Dasatinib for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome After Axicabtagene Ciloleucel Infusion: A Case Report

使用达沙替尼治疗阿西美妥昔细胞输注后难治性免疫效应细胞相关神经毒性综合征:一例病例报告

2025-09-010
PRE
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma

CD19 CAR-T在大型B细胞淋巴瘤中国际代谢预后指数的优化与验证

2025-08-260
OAAI
Severity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy

通过血清神经丝蛋白评估接受CD19靶向CAR T细胞疗法的ICANS患者中与严重程度相关的神经轴突损伤

2025-08-050
OAAI
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders

SARS-CoV-2感染对B细胞淋巴增殖性疾病患者双特异性抗体治疗的影响

2025-05-260
OAAI
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy

结外受累的大B细胞淋巴瘤的位点特异性分析揭示了嵌合抗原受体T细胞疗法的独特疗效

LEUKEMIA
IF13.4
2025-04-010
PRE